The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Niushko K.M.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdravsotsrazvitiia Rossii

Luk'ianova E.N.

V.G. Korolenko City Clinical Hospital №14, Moscow

Alekseev B.Ia.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdrava Rossii

Efremov G.D.

N.A. Lopatkin Institute of Urology and Interventional Radiology, Branch, National Medical Radiology Research Center, Ministry of Health of Russia, Moscow, Russia

Krasnov G.S.

Pirogov Russian National Research Medical University of Ministry of Healthcare of the Russian Federation

Kharitonov S.L.

National Medical Radiology Research Center, Ministry of Health of Russia, Obninsk, Russia;
V.A. Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, Russia

Pudova E.A.

V.A. Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, Russia

Kiseleva M.V.

FGBU MRNTs Minzdrava Rossii, Obninsk, Rossija

Kaprin A.D.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdrava Rossii

Kudryavtseva A.V.

National Medical Radiology Research Center, Ministry of Health of Russia, Obninsk, Russia;
V.A. Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, Russia

Identification of prognostic markers for locally advanced prostate cancer

Authors:

Niushko K.M., Luk'ianova E.N., Alekseev B.Ia., Efremov G.D., Krasnov G.S., Kharitonov S.L., Pudova E.A., Kiseleva M.V., Kaprin A.D., Kudryavtseva A.V.

More about the authors

Journal: P.A. Herzen Journal of Oncology. 2018;7(6): 19‑25

DOI: 10.17116/onkolog2018706119

Read: 1202 times

Download PDF (RU)
Contact the author
Table of contents

IDENTIFICATION OF PROGNOSTIC MARKERS FOR LOCALLY ADVANCED PROSTATE CANCER
IDENTIFICATION OF PROGNOSTIC MARKERS FOR LOCALLY ADVANCED PROSTATE CANCER

To cite this article:

Niushko KM, Luk'ianova EN, Alekseev BIa, et al. Identification of prognostic markers for locally advanced prostate cancer. P.A. Herzen Journal of Oncology. 2018;7(6):19‑25. (In Russ.)
https://doi.org/10.17116/onkolog2018706119

Подписка 2026 Онкология. Журнал им. П.А. Герцена (P.A. Herzen Journal of Oncology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Remote resu­lts of treatment of patients with prostate cancer who unde­rwent radiation therapy in a combined version. P.A. Herzen Journal of Onco­logy. 2025;(3):14-19
Global coagulation tests in pharmacological prophylaxis of venous thro­mboembolism in patients with prostate cancer after radi­cal prostatectomy. P.A. Herzen Journal of Onco­logy. 2025;(5):41-46
Application of a targeted panel to search for gene­tic variants of here­ditary breast cancer. P.A. Herzen Journal of Onco­logy. 2026;(1):18-23
Epidemiology and prevention of prostate cancer. Russian Journal of Preventive Medi­cine. 2025;(7):111-118
Cost-effectiveness analysis of triptorelin therapy for patients with prostate cancer in state healthcare system of the Russian Fede­ration. Medi­cal Technologies. Asse­ssment and Choice. 2025;(3):83-92
Machine learning models for brain tumors differential diagnosis. Russian Journal of Preventive Medi­cine. 2025;(9):87-93
Using the PathVision.ai model of medi­cal deci­sion support in morphological diagnostics of prostate cancer in biopsy mate­rial. Russian Journal of Archive of Pathology. 2025;(6):34-41
Abstract:

Objective — to identify the most reliable expression prognostic markers of lymph node-negative locally advanced prostate cancer (LAPC). Material and methods. A total of 130 samples of primary tumors from the representatives of the Caucasian race (The data of the Cancer Genome Atlas (TCGA) consortium) underwent transcriptome analysis. For differential expression analysis, the samples were divided into favorable (n=109) and unfavorable (n=21) prognosis groups according to the absence or occurrence of biochemical recurrence throughout the follow-up (at least 3 years). Only the genes that had been previously identified to be associated with prostate cancer (PC) progression were considered to improve the reliability of results in the future. Potential prognostic markers were also identified for the most common molecular subtype of PC (41 and 10 patients with favorable and unfavorable prognosis, respectively). Results. There were potential markers for the unfavorable prognosis of lymph node-negative LAPC: three genes (TWIST1, TUBB3 and CHAT) that were more highly expressed in the biochemical relapse group than in the comparison group, as well as the CYP1B1, IGSF1, EDN3, MSMV, and SERPINA3 genes that demonstrated reduced mRNA expression. Analysis of the molecular subtype characterized by the formation of TMPRSS2-ERG chimeric transcript in tumor cells showed that the potential markers of unfavorable prognosis were 6 genes: MAPK8IP2, LRFN2, CHGA, TUBB3, MYT1, and CHAT, which were more highly expressed in the biochemical recurrence group than in the comparison group, as well as the MYBPC1 and PAGE4 genes that demonstrated reduced expression. The increased expression of the CHAT and TUBB genes is a potential marker of unfavorable prognosis for both the combined sample of lymph node-negative LAPC and its most common molecular subtype. Conclusion. The authors identified a number of genes (MARK8IP2, LRFN2, CHGA, MYT1, TUBB3, and CHAT), the expression level of which correlated with relapse-free survival. The obtained results can form the basis for a diagnostic panel that after clinical testing would make it possible to create a Russian test system to predict the course of PC, which could consider the molecular subtype of the tumor.

Keywords:

prostate cancer
locally advanced prostate cancer
high-throughput sequencing
transcriptome analysis
prognostic markers

Authors:

Niushko K.M.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdravsotsrazvitiia Rossii

Luk'ianova E.N.

V.G. Korolenko City Clinical Hospital №14, Moscow

Alekseev B.Ia.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdrava Rossii

Efremov G.D.

N.A. Lopatkin Institute of Urology and Interventional Radiology, Branch, National Medical Radiology Research Center, Ministry of Health of Russia, Moscow, Russia

Krasnov G.S.

Pirogov Russian National Research Medical University of Ministry of Healthcare of the Russian Federation

Kharitonov S.L.

National Medical Radiology Research Center, Ministry of Health of Russia, Obninsk, Russia;
V.A. Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, Russia

Pudova E.A.

V.A. Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, Russia

Kiseleva M.V.

FGBU MRNTs Minzdrava Rossii, Obninsk, Rossija

Kaprin A.D.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdrava Rossii

Kudryavtseva A.V.

National Medical Radiology Research Center, Ministry of Health of Russia, Obninsk, Russia;
V.A. Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, Russia

Close metadata

References:

  1. Fedorova MS, Kudryavtseva AV, Lakunina VA, Snezhkina AV, Volchenko NN, Slavnova EN, Danilova TV, Sadritdinova AF, Mel’nikova NV, Belova AA, Klimina KM, Sidorov DV, Alekseev BYu, Kaprin AD, Dmitriev AA, Krasnov GS. Downregulation of OGDHL expression is associated with promoter hypermethylation in colorectal cancer. Molekulyarnaya biologiya. 2015;49(4):678-688. (In Russ.) https://doi.org/10.7868/S0026898415040047
  2. Oparina NYu, Snezhkina AV, Sadritdinova AF, Veselovskii VA, Dmitriev AA, Senchenko VN, Mel’nikova NV, Speranskaya AS, Darii MV, Stepanov OA, Barkhatov IM, Kudryavtseva AV. Differential expression of genes that encode glycolysis enzymes in kidney and lung cancer in humans. Genetika. 2013;49(7):814-823. (In Russ.)
  3. Cherkasova E, Malinzak E, Rao S, Takahashi Y, Senchenko VN, Kudryavtseva AV, Nickerson ML, Merino M, Hong JA, Schrump DS, Srinivasan R, Linehan WM, Tian X, Lerman MI, Childs RW. Inactivation of the von Hippel-Lindau tumor suppressor leads to selective expression of a human endogenous retrovirus in kidney cancer. Oncogene. 2011;30(47):4697-4706. https://doi.org/10.1038/onc.2011.179
  4. Jhun MA, Geybels MS, Wright JL, Kolb S, April C, Bibikova M, Ostrander EA, Fan JB, Feng Z, Stanford JL. Gene expression signature of Gleason score is associated with prostate cancer outcomes in a radical prostatectomy cohort. Oncotarget. 2017;8(26):43035-43047. https://doi.org/10.18632/oncotarget.17428
  5. Krasnov GS, Dmitriev AA, Sadritdinova AF, Volchenko NN, Slavnova EN, Danilova TV, Snezhkina AV, Mel’nikova NV, Fedorova MS, Lakunina VA, Belova AA, Nyushko KM, Alekseev BYa, Kaprin AD, Kudryavtseva AV. Molecular genetic mechanisms of drug resistance in prostate cancer. Molekulyarnaya biologiya. 2015;49(5):716-727. (In Russ.) https://doi.org/10.7868/S0026898415050110
  6. Krasnov GS, Dmitriev AA, Volchenko NN, Danilova TV, Sadritdinova AF, Snezhkina AV, Mel’nikova NV, Fedorova MS, Lakunina VA, Belova AA, Alekseev BYa, Kaprin AD, Kudryavtseva AV. Main molecular targets for prostate cancer therapy. Sibirskii onkologicheskii zhurnal. 2014;(6):45-53. (In Russ.)
  7. Dmitriev AA, Rosenberg EE, Krasnov GS, Gerashchenko GV, Gordiyuk VV, Pavlova TV, Kudryavtseva AV, Beniaminov AD, Belova AA, Bondarenko YN, Danilets RO, Glukhov AI, Kondratov AG, Alexeyenko A, Alekseev BY, Klein G, Senchenko VN, Kashuba VI. Identification of novel pigenetic markers of prostate cancer by notl-microarray analysis. Dis Markers. 2015;2015:241301. https://doi.org/10.1155/2015/241301
  8. The Cancer Genome Atlas Research Network. The molecular taxonomy of primary prostate cancer. Cell. 2015;163(4):1011-1025. https://doi.org/10.1016/j.cell.2015.10.025
  9. Dmitriev AA, Rudenko EE, Kudryavtseva AV, Krasnov GS, Gordiyuk VV, Stakhovsky EO, Kononenko OA, Pavlova LS, Kondratieva TT, Alekseev BY, Braga EA, Senchenko VN, Kashuba VI. Epigenetic alterations of chromosome 3 revealed by NotI-microarrays in clear cell renal cell carcinoma. Biomed Res Int. 2014;2014:735292. https://doi.org/10.1155/2014/735292
  10. Snezhkina AV, Krasnov GS, Zhikrivetskaya SO, Karpova IYu, Fedorova MS, Nyushko KM, Belyakov MM, Gnuchev NV, Sidorov DV, Alekseev BYa, Mel’nikova NV, Kudryavtseva AV. Overexpression of microRNAs miR-9, -98, and -199 correlates with the downregulation of HK2 expression in colorectal cancer. Molekulyarnaya biologiya. 2018;52(2):190-199. (In Russ.) https://doi.org/10.7868/S0026898418020052
  11. Kudryavtseva AV, Krasnov GS, Snezhkina AV, Nasedkina TV, Ikonnikova AYu, Ammur YuI. Identification of fusion transcripts in leukemic cells by whole-transcriptome sequencing. Molekulyarnaya biologiya. 2018;52(2):231-237. (In Russ.) https://doi.org/10.7868/S0026898418020064
  12. Snezhkina AV, Krasnov GS, Zaretsky AR, Zhavoronkov A, Nyushko KM, Moskalev AA, Karpova IY, Afremova AI, Lipatova AV, Kochetkov DV, Fedorova MS, Volchenko NN, Sadritdinova AF, Melnikova NV, Sidorov DV, Popov AY, Kalinin DV, Kaprin AD, Alekseev BY, Dmitriev AA, Kudryavtseva AV. Differential expression of alternatively spliced transcripts related to energy metabolism in colorectal cancer. BMC Genomics. 2016;17:1011. https://doi.org/10.1186/s12864-016-3351-5
  13. Krasnov GS, Puzanov GA, Kudryavtseva AV, Dmitriev AA, Beniaminov AD, Kondrateva TT, Senchenko VN. Differential expression of an ensemble of the key genes involved in cell-cycle regulation in lung cancer. Molekulyarnaya biologiya. 2017;51(5):849-856. (In Russ.) https://doi.org/10.7868/S0026898417050135
  14. Kudryavtseva AV, Fedorova MS, Zhavoronkov A, Moskalev AA, Zasedatelev AS, Dmitriev AA, Sadritdinova AF, Karpova IY, Nyushko KM, Kalinin DV, Volchenko NN, Mel’nikova NV, Klimina KM, Sidorov DV, Popov AY, Nasedkina TV, Kaprin AD, Alekseev BY, Krasnov GS, Snezhkina AV. Effect of lentivirus-mediated shRNA inactivation of HK1, HK2, and HK3 genes in colorectal cancer and melanoma cells. BMC Genetics. 2016; 17(Suppl.3):156. https://doi.org/10.1186/s12863-016-0459-1
  15. Kiseleva MV, Karpeikina MM, Komarova EV, Malinova IV, Denisov MS, Chudakov KV. Possibility for ovarian function recovery in cancer patients. Vestnik RONTs im. N.N. Blokhina RAMN. 2013;24(3-4):43-45. (In Russ.)
  16. Kiseleva MV, Komarova EV, Malinova IV, Karpeikina MM, Denisov MS. Preservation of fertility in cancer patients of reproductive age by vitrification of ovarian tissue. Reproduktivnaya meditsina. 2013;16(3-4):33-35. (In Russ.)
  17. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550. https://doi.org/10.1186/s13059-014-0550-8
  18. Cicek MS, Liu X, Casey G, Witte JS. Role of androgen metabolism genes CYP1B1, PSA/KLK3, and CYP11alpha in prostate cancer risk and aggressiveness. Cancer Epidemiol Biomarkers Prev. 2005;14(9):2173-2177. https://doi.org/10.1158/1055-9965.EPI-05-0215
  19. PLOS ONE Staff. Correction: Microseminoprotein-beta expression in different stages of prostate cancer. PLoS One. 2016;11(4): e0153732. https://doi.org/10.1371/journal.pone.0153732
  20. Sjöblom L, Saramäki O, Annala M, Leinonen K, Nättinen J, Tolonen T, Wahlfors T, Nykter M, Bova GS, Schleutker J, Tammela TL, Lilja H, Visakorpi T. Microseminoprotein-beta expression in different stages of prostate cancer. PLoS One. 2016;11(3):e0150241. https://doi.org/10.1371/journal.pone.0150241
  21. Yang GD, Yang XM, Lu H, Ren Y, Ma MZ, Zhu LY, Wang JH, Song WW, Zhang WM, Zhang R, Zhang ZG. Serpina3 promotes endometrial cancer cells growth by regulating G2/M cell cycle checkpoint and apoptosis. Int J Clin Exp Pathol. 2014;7(4):1348-1358.
  22. Abdelrahman AE, Arafa SA, Ahmed RA. Prognostic value of TWIST-1, E-cadherin and EZH2 in prostate cancer: an immunohistochemical study. Turk Patoloji Derg. 2017;Feb 4. https://doi.org/10.5146/tjpath.2017.01392
  23. Ren H, Du P, Ge Z, Jin Y, Ding D, Liu X, Zou Q. TWIST1 and BMI1 in cancer metastasis and chemoresistance. J Cancer. 2016;7(9):1074-1080. https://doi.org/10.7150/jca.14031
  24. Ploussard G, Terry S, Maillé P, Allory Y, Sirab N, Kheuang L, Soyeux P, Nicolaiew N, Coppolani E, Paule B, Salomon L, Culine S, Buttyan R, Vacherot F, de la Taille A. Class III beta-tubulin expression predicts prostate tumor aggressiveness and patient response to docetaxel-based chemotherapy. Cancer Res. 2010;70(22):9253-9264. https://doi.org/10.1158/0008-5472.CAN-10-1447
  25. Wang N, Yao M, Xu J, Quan Y, Zhang K, Yang R, Gao WQ. Autocrine activation of CHRM3 promotes prostate cancer growth and castration resistance via CaM/CaMKK-mediated phosphorylation of akt. Clin Cancer Res. 2015;21(20):4676-4685.
  26. Wang Z, Wang H, Wu J, Zhu D, Zhang X, Ou L, Yu Y, Lou Y. Enhanced co-expression of beta-tubulin III and choline acetyltransferase in neurons from mouse embryonic stem cells promoted by icaritin in an estrogen receptor-independent manner. Chem.Biol. Interact. 2009;179(2-3):375-385. https://doi.org/10.1016/j.cbi.2008.12.007
  27. Alshalalfa M, Schliekelman M, Shin H, Erho N, Davicioni E. Evolving transcriptomic fingerprint based on genome-wide data as prognostic tools in prostate cancer. Biol Cell. 2015;107(7):232-244. https://doi.org/10.1111/boc.201400097
  28. Penney KL, Sinnott JA, Fall K, Pawitan Y, Hoshida Y, Kraft P, Stark JR, Fiorentino M, Perner S, Finn S, Calza S, Flavin R, Freedman ML, Setlur S, Sesso HD, Andersson SO, Martin N, Kantoff PW, Johansson JE, Adami HO, Rubin MA, Loda M, Golub TR, Andrén O, Stampfer MJ, Mucci LA. mRNA expression signature of Gleason grade predicts lethal prostate cancer. J Clin Oncol. 2011;29(17):2391-2396. https://doi.org/10.1200/JCO.2010.32.6421
  29. Erho N, Crisan A, Vergara IA, Mitra AP, Ghadessi M, Buerki C, Bergstralh EJ, Kollmeyer T, Fink S, Haddad Z, Zimmermann B, Sierocinski T, Ballman KV, Triche TJ, Black PC, Karnes RJ, Klee G, Davicioni E, Jenkins RB. Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy. PLoS One. 2013;8(6):e66855. https://doi.org/10.1371/journal.pone.0066855
  30. Zhang X, Coleman IM, Brown LG, True LD, Kollath L, Lucas JM, Lam HM, Dumpit R, Corey E, Chéry L, Lakely B, Higano CS, Montgomery B, Roudier M, Lange PH, Nelson PS, Vessella RL, Morrissey C. SRRM4 expression and the loss of REST activity May promote the emergence of the neuroendocrine phenotype in castration-resistant prostate cancer. Clin Cancer Res. 2015;21(20):4698-4708. https://doi.org/10.1158/1078-0432.CCR-15-0157
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.